NCT04142125View on ClinicalTrials.gov

Combination Antithrombotic Treatment for Prevention of Recurrent Ischemic Stroke in Intracranial Atherosclerotic Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

101

Participants

Timeline

Start Date

February 3, 2020

Primary Completion Date

September 18, 2023

Study Completion Date

September 18, 2023

Conditions
Ischemic StrokeIntracranial Atherosclerotic Disease
Interventions
DRUG

Rivaroxaban 2.5 Mg Oral Tablet bid

Pts will receive rivaroxaban + aspirin

DRUG

Acetylsalicyclic acid 81 mg tablet qd

Pts will receive ASA

Trial Locations (10)

T2N 2T9

Alberta Health Services, Calgary

T6G 2B7

University of Alberta, Edmonton

V5Z 1M9

Vancouver General Hospital, Vancouver

L8L 2X2

Hamilton Health Sciences, Hamilton

K7L 2V7

Kingston Health Sciences Centre, Kingston

N6A 5A5

London Health Sciences Centre, London

K1Y 4E9

Ottawa Hospital Research Institute, Ottawa

N4K 6M9

Rhema Research Institute, Owen Sound

M4N 3M5

Sunnybrook Health Science Centre, Toronto

M5T 2S8

Toronto Western Hospital, Toronto

Sponsors
All Listed Sponsors
lead

Population Health Research Institute

OTHER